These payloads tell the cell to destroy a protein used to finish making other proteins. The antibody directs the protein-removing drug toward cells carrying its target.
ORM-5029 delivers the GSPT1 molecular glue degrader SMol006 using pertuzumab. Its primary preclinical abstract describes GSPT1 depletion, stress responses and antitumor activity in models. GSPT1 acts in translation termination, not RNA transcription. ORM-5029 and the CD33-directed ORM-6151 reached human studies; their linked trials are now terminated. Those trial outcomes must remain visible when describing the promise of this mechanism.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Degrader-antibody conjugate (DAC), Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Degrader-antibody conjugate (DAC), Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/